Fluasterone
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Fluasterone
- Accession Number
- DB06250
- Description
Has antiproliferative effects on HIV-1 and reduces HIV-1 replication.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Fluasterone (DB06250)
- Weight
- Average: 290.422
Monoisotopic: 290.204593652 - Chemical Formula
- C19H27FO
- Synonyms
- Not Available
- External IDs
- HE 2500
- HE-2500
Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset- Indication
Investigated for use/treatment in psoriasis and psoriatic disorders, hyperlipidemia, metabolic disease, cancer/tumors (unspecified), and obesity.
- Contraindications & Blackbox Warnings
Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects- Pharmacodynamics
- Not Available
- Mechanism of action
Fluasterone is a synthetically stable adrenocortical steroid fluorinated analogue of dehydroepiandrosterone (DHEA), a powerful anti-inflammatory molecule with androgenic or estrogenic side effects. It is proposed that fluasterone inhibits NF-kB activation and reduces oxidative stress, but other mechanisms may play a role. Fluasterone suppresses inflammation and is effective in preclinical models of chronic inflammatory disease including psoriasis, asthma, rheumatoid arthritis, multiple sclerosis and lupus erythematosus. Fluasterone has anti-inflammatory effects inpreclinical models of chronic inflammatory disease including psoriasis, asthma, rheumatoid arthritis, multiple sclerosis and lupus erythematosus. [Aeson Pharmaceuticals Executive Report]
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareBeclomethasone dipropionate The risk or severity of edema formation can be increased when Fluasterone is combined with Beclomethasone dipropionate. Betamethasone The risk or severity of edema formation can be increased when Fluasterone is combined with Betamethasone. Betamethasone phosphate The risk or severity of edema formation can be increased when Fluasterone is combined with Betamethasone phosphate. Budesonide The risk or severity of edema formation can be increased when Fluasterone is combined with Budesonide. Ciclesonide The risk or severity of edema formation can be increased when Fluasterone is combined with Ciclesonide. Clobetasol The risk or severity of edema formation can be increased when Fluasterone is combined with Clobetasol. Clobetasol propionate The risk or severity of edema formation can be increased when Fluasterone is combined with Clobetasol propionate. Corticotropin The risk or severity of edema formation can be increased when Fluasterone is combined with Corticotropin. Cortisone acetate The risk or severity of edema formation can be increased when Fluasterone is combined with Cortisone acetate. Deflazacort The risk or severity of edema formation can be increased when Fluasterone is combined with Deflazacort. 
Improve patient outcomesBuild effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.Learn more - Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as androstane steroids. These are steroids with a structure based on the 19-carbon androstane skeleton.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Steroids and steroid derivatives
- Sub Class
- Androstane steroids
- Direct Parent
- Androstane steroids
- Alternative Parents
- Halogenated steroids / 17-oxosteroids / Delta-5-steroids / Alpha-haloketones / Organofluorides / Organic oxides / Hydrocarbon derivatives / Alkyl fluorides
- Substituents
- 16-halo-steroid / 17-oxosteroid / Aliphatic homopolycyclic compound / Alkyl fluoride / Alkyl halide / Alpha-haloketone / Androstane-skeleton / Carbonyl group / Delta-5-steroid / Halo-steroid
- Molecular Framework
- Aliphatic homopolycyclic compounds
- External Descriptors
- Not Available
Chemical Identifiers
- UNII
- R7M5UGD04G
- CAS number
- 112859-71-9
- InChI Key
- VHZXNQKVFDBFIK-NBBHSKLNSA-N
- InChI
- InChI=1S/C19H27FO/c1-18-9-4-3-5-12(18)6-7-13-14(18)8-10-19(2)15(13)11-16(20)17(19)21/h6,13-16H,3-5,7-11H2,1-2H3/t13-,14+,15+,16-,18+,19+/m1/s1
- IUPAC Name
- (1S,2R,10R,11S,13R,15S)-13-fluoro-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-7-en-14-one
- SMILES
- C[C@]12CC[C@H]3[C@@H](CC=C4CCCC[C@]34C)[C@@H]1C[C@@H](F)C2=O
References
- General References
- Not Available
- External Links
- ChemSpider
- 118130
- ZINC
- ZINC000003778181
- Wikipedia
- Fluasterone
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00261 mg/mL ALOGPS logP 4.76 ALOGPS logP 4.77 ChemAxon logS -5 ALOGPS pKa (Strongest Acidic) 16.48 ChemAxon pKa (Strongest Basic) -8.2 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 1 ChemAxon Hydrogen Donor Count 0 ChemAxon Polar Surface Area 17.07 Å2 ChemAxon Rotatable Bond Count 0 ChemAxon Refractivity 82.79 m3·mol-1 ChemAxon Polarizability 33.22 Å3 ChemAxon Number of Rings 4 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created on March 19, 2008 16:19 / Updated on June 12, 2020 16:52